source
- Longevity startup NewLimit secures $435 million Series C as it prepares first liver drug trialNewLimit, a longevity‑focused biotech founded in 2021, announced a Series C financing that brought in $435 million, pushing its valuation to about $3.1 billion. The round was led by Founders Fund…
- Radiopharmaceutical shows promise after Pluvicto; Vera Therapeutics gains FDA agreement to speed IgA nephropathy data analysisA new radiopharmaceutical is generating interest for use after patients have completed Pluvicto therapy, suggesting a potential follow‑on treatment option. Abivax reported encouraging results from…